[{"orgOrder":0,"company":"BioMap","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"BioMap","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"BioMap \/ Sanofi","highestDevelopmentStatusID":"2","companyTruncated":"BioMap \/ Sanofi"}]

Find Clinical Drug Pipeline Developments & Deals by BioMap

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
filter

Year

filter

DEALS // DEV.

filter

Country

filter
Sponsor
filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

Therapeutic Area by Lead Product

ForexGraph

Study Phase by Lead Product

ForexGraph

Company by Lead Product

ForexGraph

Top Deals by Deal Size (USD bn)

ForexGraph

01

Interphex
Not Confirmed
Interphex
Not Confirmed

Details : The collaboration aims to co-develop cutting-edge AI modules for biotherapeutic drug discovery leveraging BioMap’s AI platform to discover novel targets and design biologics through a deep understanding of proteins.

Product Name : Undisclosed

Product Type : Undisclosed

Upfront Cash : $10.0 million

October 10, 2023

Lead Product(s) : Undisclosed

Therapeutic Area : Immunology

Highest Development Status : Discovery

Sponsor : Sanofi

Deal Size : $1,000.0 million

Deal Type : Collaboration

blank